• Back to Calretinin (29 kDa calbindin)

• Johnen G., Gawrych K., Raiko I., Casjens S., Pesch B., Weber D. G., Taeger D., Lehnert M., Kollmeier J., Bauer T., Musk A. W., Robinson B. W. S., Brüning T., Creaney J. Calretinin as a blood-based biomarker for mesothelioma BMC Cancer 2017; 17: 386
• Casjens S, Weber DG, Johnen G, et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population based cohort study. BMJ Open 2017;7:e017104.doi:10.1136/bmjopen-2017-017104
• Raiko I, Sander I, Weber DG, Raulf-Heimsoth M, Gillissen A, Kollmeier J, Scherpereel A, Brüning T, Johnen G. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10: 242
• Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, Müller A, Weber DG, Behrens T. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta 2014; 1844: 874-883
• Calretinin ELISA: A New Assay for the Detection of Mesothelioma in Blood Samples. Georg Johnen, Irina Raiko, Ingrid Sander, Daniel G. Weber, Monika Raulf-Heimsoth, Adrian Gillissen, Jens Kollmeier, Klaus-Michael Müller, Arnaud Scherpereel, Thomas Brüning (data on file)